Algen Biotechnologies

Algen Biotechnologies is pioneering a novel approach to drug discovery, leveraging CRISPR technology to identify and target disease-driving RNA messages. Their focus is on developing innovative treatments for cancer, inflammation, and other diseases with significant unmet medical needs. By combining the precision of CRISPR with the analytical power of machine learning, Algen aims to create first-in-class drugs that modulate RNA messages at the single-cell level. Founded by a bioengineer from the Jennifer Doudna Lab, a biotech commercialization expert, and seasoned pharmaceutical executives, Algen is poised to revolutionize RNA-targeted therapeutics.